The immunoreactivity of radiolabeled antibodies - Its impact on tumor targeting and strategies for preservation

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 6, 2004, Pages 669-672

  Reilly, Raymond ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM; ACTINIUM 225; BISMUTH 213; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 125; CETUXIMAB; CHELATING AGENT; COPPER 67; EDRECOLOMAB; INDIUM; LUTETIUM; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 198 I 125; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY B.72.3 I 125; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 I 125; MONOCLONAL ANTIBODY CC83; MONOCLONAL ANTIBODY CC83 I 125; MONOCLONAL ANTIBODY CD33; MONOCLONAL ANTIBODY L8A4 I 125; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY M 195; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ANTIBODY LABELING; ANTIGEN BINDING; BINDING AFFINITY; CANCER IMMUNOTHERAPY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; ISOTOPE LABELING; MEASUREMENT; MONOCLONAL ANTIBODY CC49 IN 11; MONOCLONAL ANTIBODY CC83 TC 99M; NONHUMAN; PRESERVATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; RADIOIODINATION; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 14044269528     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.669     Document Type: Editorial

References (28)

1. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660.
2. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabelled monoclonal antibodies by linear extrapolation of binding to infinite antigen excess. J Immunol Meth 1984;72:77.
3. Reilly RM, Sandhu J, Alvarez-Diez T, et al. Problems of delivery of monoclonal antibodies: Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126.
4. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988;48:7022.
5. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:(suppl)814s.
6. Muraro R, Kuroki M, Wunderlich D, et al. Generation and characterization of B72.3 second-generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588.
7. Gallinger S, Reilly RM, Kirsch J, et al. Comparative dual label study and second-generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53:271.
8. Divgi CR, Scott AM, McDermott K, et al. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl Med Biol 1994;21:9.
9. Fujimori K, Covell DG, Fletcher JE, et al. A modeling analysis of monoclonal antibody percolation through tumors: A binding site barrier. J Nucl Med 1990;31:1191.
10. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144.
11. Zuckier LS, Berkowitz EZ, Sattenberg RJ, et al. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 2000;60:7008.
12. Pimm MV, Baldwin RW. Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities. Eur J Nucl Med 1987;13:352.
13. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2-IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995;55:878.
14. m. Nucl Med Commun 1994;15:379.
15. Ngai WM, Reilly RM, Polihronis J, et al. In-vitro and in-vivo evaluation of streptavidin immunoconjugates of the second-generation TAG-72 monoclonal antibody CC49. Nucl Med Biol 1994;22:77.
16. Reist CJ, Batra SK, Pegram CN, et al. In vitro and in vivo behaviour of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine counterpart. Nucl Med Biol 1997;24:639.
17. Fritzberg AR, Berninger RW, Hadley SW, et al. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. Pharmaceut Res 1988;5:325.
18. Paik CH, Ebbert MA, Murphy PR, et al. Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. J Nucl Med 1983;24:1158.
19. 2 fragment of the monoclonal antibody 431/31. Nucl Med Biol 1988; 15:617.
20. Nikula TK, Bocchia M, Curcio MJ, et al. Impact of the high tyrosine fraction in complementarity determining regions: Measured and predicted effects of radioiodination on IgG immunoreactivity. Molec Immunol 1995;32:865.
21. 213Bi-labeled antibody constructs for clinical use. J Nucl Med 1999;40:1722.
22. Rodwell JD, Alvarez VL, Lee C, et al. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986;83:2632.
23. Rea DW, Ultee ME, Belinka BA, Jr, et al. Site-specifically radioiodinated antibody for targeting tumors. Cancer Res 1990;50(3 suppl):857.
24. Manabe Y, Longley C, Furmanski P. High-level conjugation of chelating agents onto immunoglobulins: Use of an intermediary poly(L-lysine)- diethylenetriameinepentaacetic acid carrier. Biochimica Biophysica Acta 1986;883:460.
25. Wen X, Wu Q-P, Lu Y, et al. Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjugate Chem 2001;12:545.
26. Wang J, Chen P, Su Z-F, et al. Amplified delivery of indium-111 to EGFR-positive breast cancer cells. Nucl Med Biol 2001;28:895.
27. Chan C, Sandhu J, Scollard DA, et al. A novel human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated radiometal binding site for indium-111 with potential for imaging tumor angiogenesis. Molec Imaging 2004;3:251.
28. Waibel R, Alberto R, Willuda J, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999;17:897.